Subramaniam et al., 2011 - Google Patents
A multivalent Mannheimia-Bibersteinia vaccine protects bighorn sheep against Mannheimia haemolytica challengeSubramaniam et al., 2011
View PDF- Document ID
- 6891819851561007155
- Author
- Subramaniam R
- Shanthalingam S
- Bavananthasivam J
- Kugadas A
- Potter K
- Foreyt W
- Hodgins D
- Shewen P
- Barrington G
- Knowles D
- Srikumaran S
- Publication year
- Publication venue
- Clinical and Vaccine Immunology
External Links
Snippet
Bighorn sheep (BHS) are more susceptible than domestic sheep (DS) to Mannheimia haemolytica pneumonia. Although both species carry M. haemolytica as a commensal bacterium in the nasopharynx, DS carry mostly leukotoxin (Lkt)-positive strains while BHS …
- 241001502414 Ovis canadensis 0 title abstract description 113
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Subramaniam et al. | A multivalent Mannheimia-Bibersteinia vaccine protects bighorn sheep against Mannheimia haemolytica challenge | |
| Hagan et al. | Uropathogenic Escherichia coli outer membrane antigens expressed during urinary tract infection | |
| Giguère et al. | Role of the 85-kilobase plasmid and plasmid-encoded virulence-associated protein A in intracellular survival and virulence of Rhodococcus equi | |
| Boyce et al. | The capsule is a virulence determinant in the pathogenesis of Pasteurella multocida M1404 (B: 2) | |
| Thom et al. | Duration of immunity against Mycobacterium bovis following neonatal vaccination with bacillus Calmette-Guérin Danish: significant protection against infection at 12, but not 24, months | |
| Eldar et al. | Development and efficacy of a vaccine against Streptococcus iniae infection in farmed rainbow trout | |
| Hatcher et al. | Recent advances in Burkholderia mallei and B. pseudomallei research | |
| Xu et al. | Role of a cytotoxic enterotoxin in Aeromonas-mediated infections: development of transposon and isogenic mutants | |
| Fortney et al. | Expression of peptidoglycan-associated lipoprotein is required for virulence in the human model of Haemophilus ducreyi infection | |
| Castañeda‐Roldán et al. | Characterization of SP41, a surface protein of Brucella associated with adherence and invasion of host epithelial cells | |
| Rojas-Hernández et al. | Intranasal coadministration of the Cry1Ac protoxin with amoebal lysates increases protection against Naegleria fowleri meningoencephalitis | |
| Skinner et al. | The order of prime-boost vaccination of neonatal calves with Mycobacterium bovis BCG and a DNA vaccine encoding mycobacterial proteins Hsp65, Hsp70, and Apa is not critical for enhancing protection against bovine tuberculosis | |
| Ayalew et al. | Immunogenicity of Mannheimia haemolytica recombinant outer membrane proteins serotype 1-specific antigen, OmpA, OmpP2, and OmpD15 | |
| Frandoloso et al. | Development and characterization of protective Haemophilus parasuis subunit vaccines based on native proteins with affinity to porcine transferrin and comparison with other subunit and commercial vaccines | |
| Bhattacharjee et al. | Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine | |
| Dale et al. | Antibodies against a synthetic peptide of SagA neutralize the cytolytic activity of streptolysin S from group A streptococci | |
| McArthur et al. | Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model | |
| Buddle et al. | Subcutaneous administration of a 10-fold-lower dose of a commercial human tuberculosis vaccine, Mycobacterium bovis bacillus Calmette-Guerin Danish, induced levels of protection against bovine tuberculosis and responses in the tuberculin intradermal test similar to those induced by a standard cattle dose | |
| Boyce et al. | Acapsular Pasteurella multocida B: 2 can stimulate protective immunity against pasteurellosis | |
| Ruffolo et al. | Iron-regulated outer membrane proteins of Pasteurella multocida and their role in immunity | |
| van den Berg et al. | Role of antibodies against Bordetella pertussis virulence factors in adherence of Bordetella pertussis and Bordetella parapertussis to human bronchial epithelial cells | |
| Willingham-Lane et al. | Influence of plasmid type on the replication of Rhodococcus equi in host macrophages | |
| Li et al. | A Streptococcus suis live vaccine suppresses streptococcal toxic shock-like syndrome and provides sequence type-independent protection | |
| Gatewood et al. | Growth-condition dependent expression of Pasteurella haemolytica A1 outer membrane proteins, capsule, and leukotoxin | |
| Island et al. | Cytotoxicity of hemolytic, cytotoxic necrotizing factor 1-positive and-negative Escherichia coli to human T24 bladder cells |